Designation Pasg News Today : Breaking News, Live Updates & Top Stories | Vimarsana

- Urgency for effective treatment underscored by European Commission designation for investigational gene therapy PBKR03
- Global Phase 1/2 trial – GALax-C – PBKR03 planned to initiate in first half of 2021
PHILADELPHIA, April 05, 2021 (GLOBE NEWSWIRE) Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for rare monogenic central nervous system (CNS) disorders, today announced that the European Commission has granted Orphan designation for PBKR03, an adeno-associated virus (AAV)-delivery gene therapy for the treatment of Krabbe disease (Globoid Cell Leukodystrophy). The designation was based on a positive opinion from the European Medicines Agency Committee for Orphan Medicinal Products. Currently, there are no approved disease-modifying therapies available for Krabbe disease, a rare lysosomal storage disease that most often presents early in a child’s life. The U.S. Food and Drug Administrat ....

University Of Pennsylvania , United States , Gwen Fisher , Stuart Henderson , Bruce Goldsmith , Exchange Commission , University Of Pennsylvania Gene Therapy Program , European Union , European Commission , Drug Administration , Passage Bio Inc , Globoid Cell Leukodystrophy , European Medicines Agency Committee , Orphan Medicinal , Fast Track , Orphan Drug , Rare Pediatric Disease , Passage Bio , Gene Therapy Program , Private Securities Litigation Reform Act , Risk Factors , Bio Investors , Bio Media , Inc Stock Exchange , Press Release , Designation Pasg ,